{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:04:30Z","timestamp":1787065470551,"version":"build-2736575974"},"reference-count":157,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) is a growing global health concern, impacting approximately 32.4% of the worldwide population. As a disease linked to metabolic dysfunction, NAFLD continues to rise alongside global increases in obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome. There is considerable evidence indicating that NAFLD disproportionately affects racial, ethnic, and minority groups, although the exact reasons for these disparities remain elusive. Contributing factors to this disease may include socioeconomic status, cultural influences, stress, genetic factors, and lifestyle choices. Emerging evidence suggests that these causal factors could influence epigenetic mechanisms, particularly DNA methylation and histone modifications, as well as the composition and diversity of gut microbiota. Nevertheless, there is a scarcity of research that comprehensively examines the interplay between epigenetic changes and gut microbiome variations in relation to NAFLD disparities across different racial and ethnic populations globally. This paper intends to (i) explore the connections between NAFLD, ethnic disparities, gut microbiota composition, and epigenetic alterations, while reviewing pertinent studies that illustrate how these factors contribute to health inequities among various ethnic groups impacted by this disease; (ii) explore potential therapeutic targets and biomarkers to advance the management of NAFLD; and (iii) provide insights to enhance our understanding of the mechanisms associated with this disease, thereby promoting further research in this field. Advancements in this area are anticipated to enhance our understanding of disease susceptibilities in at-risk groups and to provide new therapeutic options for NAFLD and its associated complications.<\/jats:p>","DOI":"10.3390\/biom15050669","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:31:36Z","timestamp":1746419496000},"page":"669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4113-4350","authenticated-orcid":false,"given":"Mohamed","family":"Zaiou","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, CNRS, IJL, F-54000 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6440-191X","authenticated-orcid":false,"given":"Olivier","family":"Joubert","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, CNRS, IJL, F-54000 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease-A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis: An Overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Heptol. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jgh.12212","article-title":"Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches","volume":"28","author":"Schuppan","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bpg.2014.07.008","article-title":"Non-alcoholic fatty liver disease, obesity and the metabolic syndrome","volume":"28","author":"Dietrich","year":"2014","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Vessby","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jhep.2023.08.021","article-title":"Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD","volume":"80","author":"Chen","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21037\/tgh.2019.12.05","article-title":"Pathogenesis and pathways: Nonalcoholic fatty liver disease & alcoholic liver disease","volume":"5","author":"Robinson","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cgh.2014.08.037","article-title":"Prevalence of suspected nonalcoholic fatty liver disease in Hispanic\/Latino individuals differs by heritage","volume":"13","author":"Kallwitz","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_16","unstructured":"Center for Disease Control [CDC], and National Center for Health Statistics (2015, March 25). Health, United States, 2008, Available online: https:\/\/www.cdc.gov\/nchs\/data\/hus\/hus08.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected Rapid Increase in the Burden of NAFLD in China from 2008 to 2018: A Systematic Review and Meta-Analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Huang, Q., Zou, X., Wen, X., Zhou, X., and Ji, L. (2021). NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results from NHANES III. Front. Med., 8.","DOI":"10.3389\/fmed.2021.693507"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cgh.2016.09.149","article-title":"Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings from the National Health and Nutrition Examination Survey","volume":"15","author":"Balakrishnan","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3350\/cmh.2023.0205","article-title":"Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study","volume":"29","author":"Nguyen","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","article-title":"Differential Clinical Characteristics and Mortality Outcomes in Persons with NAFLD and\/or MAFLD","volume":"19","author":"Nguyen","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","article-title":"The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: A meta-analysis","volume":"14","author":"Wu","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"Global NAFLD Prevalence: A Systematic Review and Meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/hepr.13947","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study","volume":"53","author":"Fujii","year":"2023","journal-title":"Hepatol. Res."},{"key":"ref_28","first-page":"404","article-title":"Epidemiology of nonalcoholic fatty liver disease in Europe: A systematic review and meta-analysis","volume":"34","author":"Cholongitas","year":"2021","journal-title":"Ann. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.32774","article-title":"Geographical similarity and differences in the burden and genetic predisposition of NAFLD","volume":"77","author":"Yip","year":"2023","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.chom.2020.07.007","article-title":"Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future","volume":"28","author":"Lang","year":"2022","journal-title":"Cell Host Microbe"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Li, D., Li, Y., Yang, S., Lu, J., Jin, X., and Wu, M. (2022). Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics. Biomed. Pharmacother., 153.","DOI":"10.1016\/j.biopha.2022.113290"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Nishiyama, M., Ohtake, N., Kaneko, A., Tsuchiya, N., Imamura, S., Iizuka, S., Ishizawa, S., Nishi, A., Yamamoto, M., and Taketomi, A. (2020). Increase of Akkermansia muciniphila by a Diet Containing Japanese Traditional Medicine Bofutsushosan in a Mouse Model of Non-Alcoholic Fatty Liver Disease. Nutrients, 12.","DOI":"10.3390\/nu12030839"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Vigliotti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hartmann, P. (2022). The Microbiome in Hepatobiliary and Intestinal Disease. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.893074"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"Rau","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Qin, Q., Yan, S., Yang, Y., Chen, J., Li, T., Gao, X., Yan, H., Wang, Y., Wang, J., and Wang, S. (2021). A Metagenome-Wide Association Study of the Gut Microbiome and Metabolic Syndrome. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.682721"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1499-3872(15)60026-1","article-title":"Gut microbiota and non-alcoholic fatty liver disease","volume":"14","author":"Gkolfakis","year":"2015","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mallott, E.K., Sitarik, A.R., Leve, L.D., Cioffi, C., Camargo, C.A., Hasegawa, K., and Bordenstein, S.R. (2023). Human microbiome variation associated with race and ethnicity emerges as early as 3 months of age. PLoS Biol., 21.","DOI":"10.1371\/journal.pbio.3002230"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Brooks, A.W., Priya, S., Blekhman, R., and Bordenstein, S.R. (2018). Gut microbiota diversity across ethnicities in the United States. PLoS Biol., 16.","DOI":"10.1101\/342915"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41591-018-0160-1","article-title":"Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography","volume":"24","author":"Deschasaux","year":"2018","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1965463","DOI":"10.1080\/19490976.2021.1965463","article-title":"Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study","volume":"13","author":"Hullar","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/hep.28677","article-title":"Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort","volume":"64","author":"Setiawan","year":"2016","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2017947118","DOI":"10.1073\/pnas.2017947118","article-title":"The human gut microbiome and health inequities","volume":"118","author":"Amato","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41575-018-0061-2","article-title":"You are what you eat: Diet, health and the gut microbiota","volume":"16","author":"Zmora","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Borrello, K., Lim, U., Park, S.Y., Monroe, K.R., Maskarinec, G., Boushey, C.J., Wilkens, L.R., Randolph, T.W., Le Marchand, L., and Hullar, M.A. (2022). Dietary Intake Mediates Ethnic Differences in Gut Microbial Composition. Nutrients, 14.","DOI":"10.3390\/nu14030660"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.chom.2020.08.005","article-title":"Human-Gut-DNA Virome Variations across Geography, Ethnicity, and Urbanization","volume":"28","author":"Zuo","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.cell.2018.10.029","article-title":"US Immigration Westernizes the Human Gut Microbiome","volume":"175","author":"Vangay","year":"2018","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.21037\/tp-21-426","article-title":"A low abundance of genus Bacteroides in gut microbiota is negatively correlated with blood phenylalanine levels in Uygur patients with phenylketonuria","volume":"10","author":"Su","year":"2021","journal-title":"Transl. Pediatr."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"He, Y., Wu, W., Wu, S., Zheng, H.M., Li, P., Sheng, H.F., Chen, M.X., Chen, Z.H., Ji, G.Y., and Zheng, Z.D. (2018). Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis. Microbiome, 6.","DOI":"10.1186\/s40168-018-0557-6"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.113.005757","article-title":"Racial\/ethnic differences in dyslipidemia patterns","volume":"129","author":"Frank","year":"2024","journal-title":"Circulation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13073-024-01295-7","article-title":"Ethnic variations in metabolic syndrome components and their associations with the gut microbiota: The HELIUS study","volume":"16","author":"Balvers","year":"2024","journal-title":"Genome Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/cvr\/cvae018","article-title":"Networks of gut bacteria relate to cardiovascular disease in a multi-ethnic population: The HELIUS study","volume":"120","author":"Warmbrunn","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","article-title":"Microbiota in health and diseases","volume":"7","author":"Hou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.cgh.2019.02.007","article-title":"American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic\/Latino Adults","volume":"17","author":"Kallwitz","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng.488","article-title":"Variant in PNPLA3 is associated with alcoholic liver disease","volume":"42","author":"Tian","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"909","DOI":"10.5604\/01.3001.0010.5282","article-title":"The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population","volume":"16","author":"Larrieta","year":"2017","journal-title":"Ann. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/oby.22527","article-title":"Genome-Wide Association Study Identifies Loci for Liver Enzyme Concentrations in Mexican Americans: The GUARDIAN Consortium","volume":"27","author":"Young","year":"2019","journal-title":"Obesity"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis","volume":"19","author":"Balakrishnan","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/hep4.1775","article-title":"Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics","volume":"5","author":"Shaheen","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhang, X., Heredia, N.I., Balakrishnan, M., and Thrift, A.P. (2021). Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252164"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Zaiou, M., Amrani, R., Rihn, B., and Hajri, T. (2021). Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091256"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/bdra.20770","article-title":"Racial differences in gene-specific DNA methylation levels are present at birth","volume":"91","author":"Adkins","year":"2011","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e20532","DOI":"10.7554\/eLife.20532","article-title":"Differential methylation between ethnic sub-groups reflects the effect of genetic ancestry and environmental exposures","volume":"6","author":"Galanter","year":"2017","journal-title":"eLife"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13148-022-01351-2","article-title":"Characterisation of ethnic differences in DNA methylation between UK-resident South Asians and Europeans","volume":"14","author":"Elliott","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/02770903.2016.1265126","article-title":"DNA methylation levels associated with race and childhood asthma severity","volume":"54","author":"Chan","year":"2017","journal-title":"J. Asthma"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-09-3342","article-title":"Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men","volume":"16","author":"Wang","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hyun, J., and Jung, Y. (2020). DNA Methylation in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218138"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e11119","DOI":"10.1016\/j.heliyon.2022.e11119","article-title":"Deciphering the role of aberrant DNA methylation in NAFLD and NASH","volume":"8","author":"Vachher","year":"2022","journal-title":"Heliyon"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Hajri, T., Zaiou, M., Fungwe, T.V., Ouguerram, K., and Besong, S. (2021). Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease. Cells, 10.","DOI":"10.3390\/cells10061355"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2337\/db18-1193","article-title":"A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease","volume":"68","author":"Ma","year":"2019","journal-title":"Diabetes"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1080\/15592294.2022.2039850","article-title":"Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children","volume":"17","author":"Moylan","year":"2022","journal-title":"Epigenetics"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Patel, P., Selvaraju, V., Babu, J.R., Wang, X., and Geetha, T. (2022). Racial Disparities in Methylation of NRF1, FTO, and LEPR Gene in Childhood Obesity. Genes, 13.","DOI":"10.3390\/genes13112030"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13148-021-01171-w","article-title":"Race\/ethnicity-associated blood DNA methylation differences between Japanese and European American women: An exploratory study","volume":"13","author":"Song","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/hep.31533","article-title":"Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations","volume":"73","author":"Wegermann","year":"2021","journal-title":"Hepatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2337\/diacare.14.7.695","article-title":"Diabetes in pregnancy in Mexican Americans","volume":"14","author":"Hollingsworth","year":"1991","journal-title":"Diabetes Care"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"107155","DOI":"10.1016\/j.phrs.2024.107155","article-title":"SIRT1: Harnessing multiple pathways to hinder NAFLD","volume":"203","author":"Tian","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jhep.2013.07.027","article-title":"Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity","volume":"59","author":"Moschen","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"goad032","DOI":"10.1093\/gastro\/goad032","article-title":"Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice","volume":"11","author":"Wang","year":"2023","journal-title":"Gastroenterol. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"852","DOI":"10.7150\/ijbs.19370","article-title":"Emerging roles of SIRT1 in fatty liver diseases","volume":"13","author":"Ding","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","article-title":"Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation","volume":"9","author":"Purushotham","year":"2009","journal-title":"Cell Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21767\/2472-1158.100058","article-title":"Single Gene Inactivation with Implications to Diabetes and Multiple Organ Dysfunction Syndrome","volume":"3","author":"Martins","year":"2017","journal-title":"J. Clin. Epigenet."},{"key":"ref_85","first-page":"1272","article-title":"The Association between SIRT1 Genetic Variation and Type 2 Diabetes Mellitus Is Influenced by Dietary Intake in Elderly Chinese","volume":"47","author":"Zhuanping","year":"2018","journal-title":"Iran. J. Public Health"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"18273","DOI":"10.1073\/pnas.0608537103","article-title":"Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men","volume":"103","author":"Petersen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1440-1746.2010.06443.x","article-title":"Nonalcoholic fatty liver disease across ethno-racial groups: Do Asian-American adults represent a new at-risk population?","volume":"26","author":"Tabibian","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.tim.2024.05.006","article-title":"Unraveling host regulation of gut microbiota through the epigenome-microbiome axis","volume":"32","author":"Pepke","year":"2024","journal-title":"Trends Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e39051","DOI":"10.1097\/MD.0000000000039051","article-title":"Gut microbiota and epigenetic choreography: Implications for human health: A review","volume":"103","author":"Kim","year":"2024","journal-title":"Medicine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2024","journal-title":"Gut"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.29646","article-title":"Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis","volume":"67","author":"Raurell","year":"2018","journal-title":"Hepatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"106807","DOI":"10.1016\/j.phrs.2023.106807","article-title":"Gut mycobiome and metabolic diseases: The known, the unknown, and the future","volume":"193","author":"Wang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Castillo, V., Figueroa, F., Gonz\u00e1lez-Pizarro, K., Jopia, P., and Ibacache-Quiroga, C. (2021). Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods, 10.","DOI":"10.3390\/foods10081719"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"G42","DOI":"10.1152\/ajpgi.00017.2023","article-title":"Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease","volume":"325","author":"Kaufmann","year":"2023","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Arellano-Garc\u00eda, L., Trepiana, J., Mart\u00ednez, J.A., Portillo, M.P., and Milton-Laskibar, I. (2023). Beneficial Effects of Viable and Heat-Inactivated Lactobacillus rhamnosus GG Administration on Oxidative Stress and Inflammation in Diet-Induced NAFLD in Rats. Antioxidants, 12.","DOI":"10.3390\/antiox12030717"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Zhang, J., Zhou, J., He, Z., and Li, H. (2024). Bacteroides and NAFLD: Pathophysiology and therapy. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1288856"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.molmet.2019.08.020","article-title":"Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice","volume":"29","author":"Zhao","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J. Gastrointestin Liver Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jn\/nxy088","article-title":"Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial","volume":"148","author":"Bakhshimoghaddam","year":"2018","journal-title":"J. Nutr."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Maurizi, V., Boccuto, L., Di Berardino, A., Giostra, N., Santori, P., Scarcella, M.L., Procopio, A.C., Rasetti, C., and Scarpellini, E. (2022). Nutritional Support in Acute Liver Failure. Diseases, 10.","DOI":"10.3390\/diseases10040108"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Mijangos-Trejo, A., Nu\u00f1o-Lambarri, N., Barbero-Becerra, V., Uribe-Esquivel, M., Vidal-Cevallos, P., and Ch\u00e1vez-Tapia, N. (2023). Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914918"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.5114\/aoms.2019.86611","article-title":"Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease","volume":"15","author":"Yao","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients with Nonalcoholic Fatty Liver Disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s12967-023-04306-0","article-title":"The effects of probiotics supplementation on glycaemic control among adults with type 2 diabetes mellitus: A systematic review and meta-analysis of randomised clinical trials","volume":"21","author":"Li","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s43066-024-00331-w","article-title":"The gut-liver nexus: Exploring gut microbiota dysbiosis in non-alcoholic fatty liver disease and its therapeutic implications","volume":"14","author":"Swamikkannu","year":"2024","journal-title":"Egypt. Liver J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cmet.2021.05.005","article-title":"Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?","volume":"33","author":"Hanssen","year":"2021","journal-title":"Cell Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17474124.2025.2450707","article-title":"Modulating the microbiome in chronic liver diseases\u2014Current evidence on the role of fecal microbiota transplantation","volume":"19","author":"Saha","year":"2025","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European consensus conference on faecal microbiota transplantation in clinical practice","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized Controlled Trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrmicro3089","article-title":"The gut microbiota and obesity: From correlation to causality","volume":"11","author":"Zhao","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Han, T.R., Yang, W., Tan, Q.H., Bai, S., Zhong, H., Tai, Y., and Tong, H. (2023). Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1004911"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Maestri, M., Santopaolo, F., Pompili, M., Gasbarrini, A., and Ponziani, F.R. (2023). Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1110536"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Xue, L., Deng, Z., Luo, W., He, X., and Chen, Y. (2022). Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.759306"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2223330","DOI":"10.1080\/19490976.2023.2223330","article-title":"Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: A multi-omics approach","volume":"15","author":"Mak","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?","volume":"158","author":"Warmbrunn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cmet.2017.09.008","article-title":"Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition","volume":"26","author":"Kootte","year":"2017","journal-title":"Cell Metab."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Hamamah, S., Iatcu, O.C., and Covasa, M. (2024). Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Nutrients, 17.","DOI":"10.3390\/nu17010143"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"100022","DOI":"10.1016\/j.cdnut.2022.100022","article-title":"Design and Implementation of a Culturally-Tailored Randomized Pilot Trial: Puerto Rican Optimized Mediterranean-Like Diet","volume":"7","author":"Mattei","year":"2022","journal-title":"Curr. Dev. Nutr."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymeth.2020.06.022","article-title":"Modern epigenetics methods in biological research","volume":"187","author":"Li","year":"2021","journal-title":"Methods"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.cmet.2019.03.009","article-title":"Epigenetics in Human Obesity and Type 2 Diabetes","volume":"29","author":"Ling","year":"2019","journal-title":"Cell Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","article-title":"Epigenetic drugs in cancer therapy","volume":"44","author":"Suraweera","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3892\/or.2023.8496","article-title":"Modulating epigenetic modifications for cancer therapy (Review)","volume":"49","author":"Ulloa","year":"2023","journal-title":"Oncol. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.molmet.2018.11.001","article-title":"Tannic acid, a novel histone acetyltransferase inhibitor, prevents non-alcoholic fatty liver disease both in vivo and in vitro model","volume":"19","author":"Chung","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","article-title":"The Essential Medicinal Chemistry of Curcumin","volume":"60","author":"Nelson","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3138\/canlivj-2023-0022","article-title":"Effects of curcumin in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"7","author":"Malik","year":"2024","journal-title":"Can. Liver J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/s-0043-100019","article-title":"Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial","volume":"67","author":"Panahi","year":"2017","journal-title":"Drug Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/157340606776056133","article-title":"Curcumin is an inhibitor of p300 histone acetylatransferase","volume":"2","author":"Marcu","year":"2006","journal-title":"Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Saadati, S., Sadeghi, A., Mansour, A., Yari, Z., Poustchi, H., Hedayati, M., Hatami, B., and Hekmatdoost, A. (2019). Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterol., 19.","DOI":"10.1186\/s12876-019-1055-4"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","article-title":"Herbal drug discovery for the treatment of nonalcoholic fatty liver disease","volume":"10","author":"Yan","year":"2020","journal-title":"Acta Pharm. Sin. B."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutr. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1111\/dom.13409","article-title":"No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease","volume":"20","author":"Poulsen","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Jakubczyk, K., Skonieczna-\u017bydecka, K., Ka\u0142du\u0144ska, J., Stachowska, E., Gutowska, I., and Janda, K. (2020). Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis. Nutrients, 12.","DOI":"10.3390\/nu12082435"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/hep.29127","article-title":"The Histone Methyltransferase Suv39h2 Contributes to Nonalcoholic Steatohepatitis in Mice","volume":"65","author":"Fan","year":"2017","journal-title":"Hepatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/1751-2980.12610","article-title":"Fatty liver mediated by peroxisome proliferator-activated receptor-? DNA methylation can be reversed by a methylation inhibitor and curcumin","volume":"19","author":"Li","year":"2018","journal-title":"J. Dig. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41401-021-00725-1","article-title":"Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis","volume":"43","author":"Huang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.curtheres.2025.100787","article-title":"Unleashing the Potential of Givinostat: A Novel Therapy for Duchenne Muscular Dystrophy","volume":"102","author":"Anjum","year":"2025","journal-title":"Cur. Ther. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/acs.jafc.2c01461","article-title":"The Ameliorating Effects of Apple Polyphenol Extract on High-Fat-Diet-Induced Hepatic Steatosis Are SIRT1-Dependent: Evidence from Hepatic-Specific SIRT1 Heterozygous Mutant C57BL\/6 Mice","volume":"70","author":"Yin","year":"2022","journal-title":"J. Agric. Food Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.2337\/db14-0263","article-title":"SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis","volume":"63","author":"Xu","year":"2014","journal-title":"Diabetes"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/13813455.2022.2046106","article-title":"Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a\/SIRT1 axis","volume":"130","author":"BinMowyna","year":"2024","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.fct.2012.10.030","article-title":"Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils","volume":"52","author":"Ying","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e136952","DOI":"10.5812\/ijpr-136952","article-title":"Hepatic Steatosis Alleviated by a Novel Metformin and Quercetin Combination Activating Autophagy Through the cAMP\/AMPK\/SIRT1 Pathway","volume":"22","author":"Afshari","year":"2023","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100513","DOI":"10.1016\/j.jlr.2024.100513","article-title":"Histone demethylase KDM1A promotes hepatic steatosis and inflammation by increasing chromatin accessibility in NAFLD","volume":"65","author":"Yang","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2012-302962","article-title":"Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease","volume":"62","author":"Pirola","year":"2013","journal-title":"Gut"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13148-021-01129-y","article-title":"Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clin","volume":"13","author":"Johnson","year":"2021","journal-title":"Epigenetics"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Erhartova, D., Cahova, M., Dankova, H., Heczkova, M., Mikova, I., Sticova, E., Spicak, J., Seda, O., and Trunecka, P. (2019). Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224820"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3892\/mmr.2021.12137","article-title":"Circulating microRNA 135a 3p in serum extracellular vesicles as a potential biological marker of non alcoholic fatty liver disease","volume":"24","author":"Jiang","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"102547","DOI":"10.1016\/j.clinre.2025.102547","article-title":"A class of MicroRNAs as diagnostic biomarkers and therapeutic strategies in non-alcoholic fatty liver disease: A review","volume":"49","author":"Mahdizadeh","year":"2025","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Zaiou, M. (2020). The Emerging Role and Promise of Circular RNAs in Obesity and Related Metabolic Disorders. Cells, 9.","DOI":"10.3390\/cells9061473"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/15476286.2023.2290769","article-title":"Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance","volume":"21","author":"Zeng","year":"2024","journal-title":"RNA Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3960197","DOI":"10.1155\/2017\/3960197","article-title":"circRNA_0046367 Prevents Hepatoxicity of Lipid Peroxidation: An Inhibitory Role against Hepatic Steatosis","volume":"2017","author":"Guo","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3748\/wjg.v24.i3.323","article-title":"circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling","volume":"24","author":"Guo","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Li, J., Qi, J., Tang, Y., Liu, H., Zhou, K., Dai, Z., Yuan, L., and Sun, C. (2021). A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p\/miR-320a and ABCA1\/CPT1 axis. J. Nanobiotechnol., 19.","DOI":"10.1186\/s12951-021-01108-8"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.jhep.2023.08.019","article-title":"Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020","volume":"80","author":"Luo","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Stronks, K., Snijder, M.B., Peters, R.J., Prins, M., Schene, A.H., and Zwinderman, A.H. (2013). Unravelling the impact of ethnicity on health in Europe: The HELIUS study. BMC Public Health, 13.","DOI":"10.1186\/1471-2458-13-402"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Riazi, K., Swain, M.G., Congly, S.E., Kaplan, G.G., and Shaheen, A.A. (2022). Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review. Nutrients, 14.","DOI":"10.3390\/nu14214556"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/gutjnl-2020-322753","article-title":"Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function","volume":"70","author":"Frost","year":"2021","journal-title":"Gut"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/5\/669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:27:10Z","timestamp":1760030830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/5\/669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":157,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["biom15050669"],"URL":"https:\/\/doi.org\/10.3390\/biom15050669","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}